Multiple cutaneous squamous cell carcinomas in a patient with interferon γ receptor 2 (IFNγR2) deficiency

Journal of Medical Genetics

Volumn 47, Issue 9, 2010, Pages 631-634

  Toyoda, Hidemi ^a,b   Ido, Masaru ^a,b   Nakanishi, Kyoichi ^a,b   Nakano, Takashi ^c   Kamiya, Hitoshi ^c   Matsumine, Akihiko ^b   Uchida, Atsumasa ^b   Mizutani, Hitoshi ^b   De Beaucoudrey, Ludovic ^d   Vogt, Guillaume ^d   Boisson Dupuis, Stéphanie ^d,e   Bustamante, Jacinta ^d   Casanova, Jean Laurent ^d,e   Komada, Yoshihiro ^b  

^a National Hospital Organization Mie Chuo Medical Center   (Japan)

^b MIE UNIVERSITY   (Japan)

^c MIE NATIONAL HOSPITAL   (Japan)

^d UNIVERSITÉ PARIS DESCARTES   (France)

^e ROCKEFELLER UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON RECEPTOR; INTERFERON GAMMA RECEPTOR 2; UNCLASSIFIED DRUG;

ADOLESCENT; ARM AMPUTATION; ARTICLE; ATYPICAL MYCOBACTERIOSIS; CANCER PATIENT; CANCER SURGERY; CANCER SUSCEPTIBILITY; CASE REPORT; DISEASE PREDISPOSITION; EPIDERMODYSPLASIA VERRUCIFORMIS; FACE; FRAMESHIFT MUTATION; GENE DELETION; HAND; HISTOPATHOLOGY; HOMOZYGOSITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IFNGR2 GENE; IMMUNE DEFICIENCY; INTERFERON GAMMA RECEPTOR 2 DEFICIENCY; LEUKEMIA; MYCOBACTERIUM FORTUITUM; MYCOBACTERIUM PORCIUM; NONHUMAN; PRIORITY JOURNAL; RARE DISEASE; RECEPTOR GENE; SKIN CARCINOMA; SQUAMOUS CELL CARCINOMA; TUMOR DIFFERENTIATION;

ADOLESCENT; AMINO ACID SEQUENCE; BASE SEQUENCE; CARCINOMA, SQUAMOUS CELL; CHILD; CHILD, PRESCHOOL; DNA MUTATIONAL ANALYSIS; GENOTYPE; HUMANS; INFANT; INFANT, NEWBORN; MALE; MOLECULAR SEQUENCE DATA; RECEPTORS, INTERFERON; SKIN NEOPLASMS; STAINING AND LABELING;

ATYPICAL MYCOBACTERIUM; MYCOBACTERIUM; MYCOBACTERIUM AVIUM; MYCOBACTERIUM FORTUITUM;

EID: 77956102454     PISSN: 00222593     EISSN: 14686244     Source Type: Journal    
DOI: 10.1136/jmg.2009.072108     Document Type: Article

References (41)

1. Diepgen TL, Mahler V. The epidemiology of skin cancer. Br J Dermatol 2002;146:1-6.
2. Alam M, Ratner D. Cutaneous squamous-cell carcinoma. N Engl J Med 2001;344:975-83.
3. Bouwes Bavinck JN, Hardie DR, Green A, Cutmore S, MacNaught A, O'Sullivan B, Siskind V, Van Der Woude FJ, Hardie IR. The risk of skin cancer in renal transplant recipients in Queensland, Australia. A follow-up study. Transplantation 1996;6:715-21.
4. Ducloux D, Carron PL, Rebibou JM, Aubin F, Fournier V, Bresson-Vautrin C, Blanc D, Humbert P, Chalopin JM. CD4 lymphocytopenia as a risk factor for skin cancers in renal transplant recipients. Transplantation 1998;65:1270-2.
5. O'Donovan P, Perrett CM, Zhang X, Montaner B, Xu YZ, Harwood CA, McGregor JM, Walker SL, Hanaoka F, Karran P. Azathioprine and UVA light generate mutagenic oxidative DNA damage. Science 2005;309:1871-4.
6. Stern RS, Laird N, Melski J, Parrish JA, Fitzpatrick TB, Bleich HL. Cutaneous squamous-cell carcinoma in patients treated with PUVA. N Engl J Med 1984;310:1156-61.
7. Orth G. Genetics of epidermodysplasia verruciformis: Insights into host defense against papillomaviruses. Semin Immunol 2006;18:362-74.
8. Euvrard S, Kanitakis J, Claudy A. Skin cancers after organ transplantation. N Engl J Med 2003;348:1681-91.
9. Rowe DE, Carroll RJ, Day CL Jr. Prognostic factors for local recurrence, metastasis, and survival rates in squamous cell carcinoma of the skin, ear, and lip. Implications for treatment modality selection. J Am Acad Dermatol 1992;26:976-90.
10. Varan A, Gököz A, Akyüz C, Kutluk T, Yalçin B, Köksal Y, Büyükpamukçu M. Primary malignant skin tumors in children: etiology, treatment and prognosis. Pediatr Int 2005;47:653-7.
11. Kraemer KH, Lee MM, Scotto J. DNA repair protects against cutaneous and internal neoplasia: evidence from xeroderma pigmentosum. Carcinogenesis 1984;5:511-14.
12. Jacyk WK. Xeroderma pigmentosum in black South Africans. Int J Dermatol 1999;38:511-14.
13. Bhutto AM, Shaikh A, Nonaka S. Incidence of xeroderma pigmentosum in Larkana, Pakistan: a 7-year study. Br J Dermatol 2005;152:545-51.
14. Gül U, Kiliç A, Gönül M, Cakmak SK, Soylu S. Xeroderma pigmentosum: a Turkish case series. Int J Dermatol 2007;46:1125-8.
15. Saghari S, Woolery-Lloyd H, Nouri K. Squamous cell carcinoma in a patient with Netherton's syndrome. Int J Dermatol 2002;41:415-16.
16. Kawasaki H, Sawamura D, Iwao F, Kikuchi T, Nakamura H, Okubo S, Matsumura T, Shimizu H. Squamous cell carcinoma developing in a 12-year-old boy with nonHallopeau-Siemens recessive dystrophic epidermolysis bullosa. Br J Dermatol 2003;148:1047-50.
17. Jacyk WK, La Cock A. Squamous cell carcinoma arising in CHILD syndrome. J Eur Acad Dermatol Venereol 2006;20:311-13.
18. Doede T, Wollina U, Hindermann W, Schier F, Bondartschuk M. Pansclerotic morphea in childhood: a case report. Pediatr Surg Int 2003;19:406-8.
19. Hidvegi NC, Kangesu L, Wolfe KQ. Squamous cell carcinoma complicating naevus sebaceous of Jadassohn in a child. Br J Plast Surg 2003;56:50-2.
20. Casanova JL, Abel L. Primary immunodeficiencies: a field in its infancy. Science 2007;317:617-19.
21. Lazarczyk M, Pons C, Mendoza JA, et al. Regulation of cellular zinc balance as a potential mechanism of EVER-mediated protection against pathogenesis by cutaneous oncogenic human papillomaviruses. J Exp Med 2008;205:35-42.
22. Toyoda H, Ido M, Hayashi T, et al. Impairment of IL-12-dependent STAT4 nuclear translocation in a patient with recurrent Mycobacterium avium infection. J Immunol 2004;172:3905-12.
23. Filipe-Santos O, Bustamante J, Chapgier A, et al. Inborn errors of IL-12/23- and IFN-gamma-mediated immunity: molecular, cellular, and clinical features. Semin Immunol 2006;18:347-61.
24. Dorman SE, Holland SM. Mutation in the signal-transducing chain of the interferongamma receptor and susceptibility to mycobacterial infection. J Clin Invest 1998;101:2364-9.
25. Rosenzweig SD, Dorman SE, Uzel G, et al. A novel mutation in IFN-gamma receptor 2 with dominant negative activity: biological consequences of homozygous and heterozygous states. J Immunol 2004;173:4000-8.
26. Vogt G, Chapgier A, Yang K, et al. Gains of glycosylation comprise an unexpectedly large group of pathogenic mutations. Nat Genet 2005;37:692-700.
27. Vogt G, Bustamante J, Chapgier A, et al. Complementation of a pathogenic IFNGR2 misfolding mutation with modifiers of N-glycosylation. J Exp Med 2008;205:1729-37.
28. Döffinger R, Jouanguy E, Dupuis S, et al. Partial interferon-gamma receptor signaling chain deficiency in a patient with bacille Calmette-Guérin and Mycobacterium abscessus infection. J Infect Dis 2000;181:379-84.
29. Syrjänen KJ. HPV infections and oesophageal cancer. J Clin Pathol 2002;55:721-8.
30. Harwood CA, Surentheran T, McGregor JM, Spink PJ, Leigh IM, Breuer J, Proby CM. Human papillomavirus infection and non-melanoma skin cancer in immunosuppressed and immunocompetent individuals. J Med Virol 2000;61:289-97.
31. Camcioglu Y, Picard C, Lacoste V, Dupuis S, Akçakaya N, Cokura H, Kaner G, Demirkesen C, Plancoulaine S, Emile JF, Gessain A, Casanova JL. HHV-8-associated Kaposi sarcoma in a child with IFNgammaR1 deficiency. J Pediatr 2004;144:519-23.
32. Dunn GP, Koebel CM, Schreiber RD. Interferons, immunity and cancer immunoediting. Nat Rev Immunol 2006;6:836-48.
33. Gresser I, Coppey J, Bourali C. Interferon and murine leukemia. VI. Effect of interferon preparations on the lymphoid leukemia of AKR mice. J Natl Cancer Inst 1969;43:1083-9.
34. Dighe AS, Richards E, Old LJ, Schreiber RD. Enhanced in vivo growth and resistance to rejection of tumour cells expressing dominant negative IFN gamma receptors. Immunity 1994;1:447-56.
35. Blankenstein T, Qin Z. Chemical carcinogens as foreign bodies and some pitfalls regarding cancer immune surveillance. Adv Cancer Res 2003;90:179-207.
36. Kaplan DH, Shankaran V, Dighe AS, Stockert E, Aguet M, Old LJ, Schreiber RD. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci U S A 1998;95:7556-61.
37. Street SE, Cretney E, Smyth MJ. Perforin and interferon-gamma activities independently control tumor initiation, growth, and metastasis. Blood 2001;97:192-7.
38. Wu TH, Pabin CN, Qin Z, Blankenstein T, Philip M, Dignam J, Schreiber K, Schreiber H. Long-term suppression of tumor growth by TNF requires a Stat1- and IFN regulatory factor 1-dependent IFN-gamma pathway but not IL-12 or IL-18. J Immunol 2004;172:3243-51.
39. Nastala CL, Edington HD, McKinney TG, Tahara H, Nalesnik MA, Brunda MJ, Gately MK, Wolf SF, Schreiber RD, Storkus WJ, Lotze MT. Recombinant IL-12 administration induces tumor regression in association with IFN-gamma production. J Immunol 1994;153:1697-706.
40. Noguchi Y, Jungbluth A, Richards EC, Old LJ. Effect of interleukin 12 on tumor induction by 3-methylcholanthrene. Proc Natl Acad Sci U S A 1996;93:11798-801.
41. Smyth MJ, Crowe NY, Godfrey DI. NK cells and NKT cells collaborate in host protection from methylcholanthrene-induced fibrosarcoma. Int Immunol 2001;13:459-63.